Synlett 2010(3): 467-469  
DOI: 10.1055/s-0029-1219177
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

A Scalable Synthesis of (±)-2-Oxoclopidogrel

Janna Veldera, Christoph Hirschhäusera, Christopher Waldmanna, Dirk Taubertb, Heleen J. Boumanc, Hans-Günther Schmalz*a
a Department für Chemie, Universität zu Köln, Greinstr. 4, 50939 Köln, Germany
Fax: +49(221)4703064; e-Mail: schmalz@uni-koeln.de;
b Institut für Pharmakologie, Universitätsklinikum Köln, Gleveler Str. 24, 50931 Köln, Germany
c St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands
Further Information

Publication History

Received 29 October 2009
Publication Date:
07 January 2010 (online)

Abstract

As a precondition for detailed pharmacological investigations, an efficient chemical method for the conversion of the antiplatelet drug clopidogrel into its first metabolite 2-oxoclopidogrel was developed. The one-pot procedure, which can easily be performed on a gram scale, exploits the selective borylation of a di-­anionic intermediate derived from clopidogrel with subsequent oxidative workup.

    References

  • 1a Yusuf S. Zhao F. Mehta SR. Chrolavicius S. Tognoni G. Fox KK. New Engl. J. Med.  2001,  345:  494 
  • 1b Mehta SR. Yusuf S. Peters RJ. Bertrand ME. Lewis BS. Natarajan MK. Malmberg K. Rupprecht H. Zhao F. Chrolavicius S. Copland I. Fox KA. Lancet  2001,  358:  527 
  • 2a Wang TH. Bhatt DL. Topol EJ. Eur. Heart J.  2006,  27:  647 
  • 2b Gurbel PA. Bliden KP. Hiatt BL. O’Connor CM. Circulation  2003,  107:  2908 
  • 3a Matetzky S. Shenkman B. Guetta V. Shechter M. Bienart R. Goldenberg I. Novikov I. Pres H. Savion N. Varon D. Hod H. Circulation  2004,  109:  3171 
  • 3b Gurbel PA. Bliden KP. Samara W. Yoho JA. Hayes K. Fissha MZ. Tantry US. J. Am. Coll. Cardiol.  2005,  46:  1827 
  • 3c Hochholzer W. Trenk D. Bestehorn HP. Fischer B. Valina CM. Ferenc M. Gick M. Caputo A. Buttner HJ. Neumann FJ. J. Am. Coll. Cardiol.  2006,  48:  1742 
  • 4a Savi P. Pereillo JM. Uzabiaga MF. Combalbert J. Picard C. Maffrand JP. Pascal M. Herbert JM. Thromb. Haemost.  2000,  84:  891 
  • 4b Pereillo JM. Maftouh M. Andrieu A. Uzabiaga MF. Fedeli O. Savi P. Pascal M. Herbert JM. Maffrand JP. Picard C. Drug Metab. Dispos.  2002,  30:  1288 
  • 4c Clarke T. Waskell LA. Drug Metab. Dispos.  2003,  31:  53 
  • 5a Von Beckerath N. Taubert D. Pogatsa-Murray G. Schomig E. Kastrati A. Schomig A. Circulation  2005,  112:  2946 
  • 5b Wallentin L. Varenhorst C. James S. Erlinge D. Braun OO. Jakubowski JA. Sugidachi A. Winters KJ. Siegbahn A. Eur. Heart J.  2008,  29:  21 
  • 6a Angiolillo DJ. Fernandez-Ortiz A. Bernardo E. Ramirez C. Cavallari U. Trabetti E. Sabate M. Hernandez R. Moreno R. Escaned J. Alfonso F. Banuelos C. Costa MA. Bass TA. Pignattim PF. Macaya C. Arterioscler., Thromb., Vasc. Biol.  2006,  26:  1895 
  • 6b Brandt JT. Close SL. Iturria SJ. Payne CD. Farid NA. Ernest CS. Lachno DR. Salazar D. Winters KJ. J. Thromb. Haemost.  2007,  5:  2429 
  • 6c Mega JL. Close SL. Wiviott SD. Shen L. Hockett RD. Brandt JT. Walker JR. Antman EM. Macias W. Braunwald E. Sabatine MS. New Engl. J. Med.  2009,  360:  354 
  • 7 Boigegrain R, Maffrand J.-P, Suzuki N, Matsubayashi K, and Ashida S. inventors; US  4,515,951. 
  • 8a Prakash C. Saleh S. Blair IA. Tetrahedron Lett.  1989,  30:  19 
  • 8b Ikawa T. Hattori K. Sajiki H. Hirota K. Tetrahedron  2004,  60:  6901 
  • 8c Paquette LA. Collado I. Purdie M. J. Am. Chem. Soc.  1998,  120:  2553 
  • 8d Fürstner A. Weintritt H. J. Am. Chem. Soc.  1998,  120:  2817 
  • 8e Batten RJ. Dixon AJ. Taylor RK. Synthesis  1980,  234 
  • 9 Dess DB. Martin JC. J Am. Chem. Soc.  1991,  113:  7277 
  • 10 Bowden K. Heilbron IM. Jones ERH. Weedon BCL. J. Chem. Soc.  1946,  39